Abstract. Our studies are aimed at determining whether pregnancy induces a specific genomic signature in the postmenopausal breast that is responsible for the protective effect elicited by this physiological process. For this purpose we designed a study to compare the gene expression profiles in normal breast tissue from parous postmenopausal women with (case) and without (control) breast cancer. We have used breast samples from 18 parous controls and 41 parous cases. The epithelium and the interlobular stroma were dissected using laser capture microdissection and the RNA of each compartment and each sample was isolated, amplified using PCR methodology, and hybridized to cDNA glass-microarrays containing 40,000 genes, placing the human reference RNA in the green channel (Cy3) and the breast tissue samples in the red channel (Cy5). The normalization and statistical analysis of the expression data were carried out by using the LIMMA software package for the R programming environment which provides functions to summarize the results using the linear model perform hypothesis tests and adjust the p-values for multiple testing. We were able to identify 126 genes that were upregulated and 103 that were downregulated in the parous control group. There were only 56 genes differentially expressed in the interlobular stroma in the parous control group in relation to the other group of women under study. The gene categories that were overrepresented in the breast epithelium of the parous control breast are related to apoptosis, DNA repair, response to exogenous agents and transcription regulation. In the present study we demonstrate that full-term pregnancy imprints a specific genomic signature in the breast epithelium of postmenopausal parous control women that is significantly different from women who have developed cancer. This genomic signature induced by pregnancy could help to predict in which women parity is protective.
Introduction
Breast cancer is the most common neoplastic disease in women and accounts for up to one third of all new cancer cases in North American women (1) . There is substantial evidence that breast cancer risk relates to endocrinologic and reproductive factors. Breast cancer development is strongly dependent on the ovary and on endocrine conditions modulated by ovarian function, such as early menarche, late menopause, and parity (1) (2) (3) (4) . Epidemiological findings indicate that a lifetime risk decrease has been observed in parous women whose first pregnancy was completed before age 24 (2) (3) (4) (5) (6) . However, the protection conferred by early first full-term pregnancy does not occur in all women. We have postulated that a cluster of genes associated with early first full-term pregnancy would be absent or modified in the breast of high-risk women, i.e., nulliparous women with cancer and also in parous women who developed cancer (7) (8) (9) . Furthermore, those genes whose expression may be affected by pregnancy and that can be proven to be functionally relevant in protecting the breast from cancer development could serve as markers for evaluating cancer risk in large populations. In the present study we demonstrate that early first full-term pregnancy induces a genomic signature that is specific for the parous breast and that is different from that in those who are parous and have cancer.
Materials and methods
Sample collection. In this study we have included postmenopausal women who underwent breast biopsies (excluding fine needle biopsies) at FCCC or the participant's hospital Christiana Care and Somerset Medical Center between October 1, 2002 and December 30, 2006 . Each participant had signed their respective informed consent forms that were approved by each Institution's Human Subjects Protection Committee. Women were 50+ years old and postmenopausal, defined as at least one year since last menses if menopause occurred naturally. We have excluded from our study women in which both ovaries were removed or with a history of cancer other than non-melanoma skin cancer, women taking medications that could interfere with the study protocol such as estrogens (including Tamoxifen and Raloxifene), progestins, androgens, prednisone, thyroid hormones, or insulin, and women with Alzheimer's disease or severe cognitive deficit who were unable to give informed consent.
Breast tissue specimens. A total of 59 histologically normal breast tissues from 18 parous controls and 41 parous cases were analyzed and microdissected for the epithelium from type 1 lobules (10, 11) and the interlobular stroma by using the laser capture microdissection (LCM) system (12) . All the tissues were collected and fixed in 70% ethanol within 10 min of surgical removal. The tissues were embedded in paraffin. Eight-micron sections were obtained and stained with hematoxylin and eosin, followed by 5-min dehydration steps in 70, 95 and 100% ethanol. Once air-dried the sections were laser microdissected with an AutoPix 1000 LCM system from Arcturus Engineering (Mountain View, CA). We captured epithelial cells from the type 1 lobules and interlobular stroma from each breast sample.
RNA isolation, labeling and cDNA human microarrays. The RNA was isolated by placing the LCM cap in 50 μl of Trizol reagent and following procedures previously described (12) . The probes were constructed using direct labeling of the random hexamer primer and following protocols described elsewhere (12) . The probes were cleaned with a QIA-quick PCR purification kit (Qiagen); PB buffer (500 μl from kit) was added into the Cy3-and Cy5-labeled products. The samples were applied to QIA-quick columns, which were centrifuged at 13,000 rpm (16,000 x g) for 1 min, after which the flow-through was discarded. The column was washed by adding 750 μl of 80% cold ethanol, and spun again for 1 min, and the flow-through was discarded. The washing was repeated twice, and the columns were spun again to remove residual ethanol. The collected material was diluted in 30 μl of DEPCwater heated at 70˚C followed by 3-min incubation at 70˚C. Columns were then centrifuged at 13,000 rpm (16,000 x g) for 1 min, and the elution step was performed only once. The eluted material was partially dried in a vacuum centrifuge and the volume was adjusted to 15 μl of hybridization buffer [containing 20X saline-sodium citrate (SSC) and 0.6 μl of 10% (wt/vol) SDS], then the probes were denatured at 95˚C for 3 min and centrifuged for 3 min at 13,000 rpm. The products were pipetted onto arrays, coverslipped, and the slides were placed in a hybridization chamber (Gene Machine). Arrays were incubated in a water bath at 42˚C for 16-18 h, and subsequently washed with 0.5X SSC, 0.01% (wt/vol) SDS, followed by 0.06X SSC, at room temperature for 10 min each. The slides were spun for 8 min at 800 rpm (130 x g) at room temperature.
Array scanning. Arrays were read with an Affymetrix 428 fluorescent scanner (MWG, CA) at 10-μm resolution and variable photomultiplier tube (PMT) voltage settings to obtain the maximal signal intensities with <1% (wt/vol) probe saturation. The resulting images were analyzed using ImaGene software version 4.2 (Biodiscovery, CA). The glass microarrays were hybridized in all the cases placing the amplified RNA from the breast samples in the red channel (labeled with Cy5) and the amplified RNA from human universal reference (Stratagene, Inc, CA) in the green channel (labeled with Cy3). We studied gene expression in the 59 patients by triplicate using cDNA microarrays, which were prepared by robotically spotting 40,000 human cDNA on mirror glass slides (NCIsupported Microarray Facility from Fox Chase Cancer Center). The cDNA included approximately 28,000 different genes that represented characterized human proteins and 10,000 identified by ESTs, the rest were controls and blank spots. The identities of the cDNA had been sequence-verified. Each hybridization compared Cy5-labelled cDNA reverse transcribed from amplified RNA isolated from each patient with the Cy3-labelled cDNA reverse transcribed from a universal human reference amplified RNA sample. The reference sample was used in all the hybridizations employing the same probe for all of them in order to have an equal and common reference for the experiment. The fluorescent probes were performed in triplicate and after checking the quality, replicates from the same sample were combined and re-distributed into 3 separate tubes in order to have an identical replicate. Equal amounts of fluorescent probes were used to hybridize the cDNA microarrays.
Data analysis.
Normalization and statistical analysis of the expression data were carried out by using the LIMMA software package for the R programming environment (13, 14) . This package contains a number of analysis methods not found in other software. Local background subtraction usually produces log-ratios that are very variable at low intensities. Because it was desired to detect differential expression for genes that might not necessarily be highly expressed, filtering out lowintensity spots was avoided. Instead, a strategy of background correction was used that avoids exaggerated variability of log-ratios for low-intensity spots. Background correction was performed by using the 'normexp' method in LIMMA to adjust the local median background estimates. This strategy is similar to the background correction method used by the popular RMA software for Affymetrix data (15) . It avoids problems with background estimates that are greater than foreground values and ensures that there were no missing or negative corrected intensities. An offset of 100 was used for both channels to further damp down the variability of logratios for low-intensity spots. The resulting log-ratios were normalized by using the print-tip group Lowess method with a span of 0.4, as recommended by Smyth and Speed (16) . Here and elsewhere, the small number of spots that were manually marked as 'bad' on visual inspection of the scanned arrays were filtered out of the analysis, while spots that were flagged as 'not found' by GENESIGHT were kept in the analysis but downweighted. The arrays used in these experiments were from four different print runs that were all printed with the same elements but with slightly different print layouts. The arrays from the different print runs were therefore normalized separately and the normalized expression data were combined and aligned by probe for subsequent analysis. After normalization of the data, each microarray had similar distributions in order to eliminate the microarray effect once we detected the gene expression of certain genes.
The basic statistic used for significance analysis is the moderated t-statistic, which is computed for each probe and for each contrast. This has the same interpretation as an ordinary t-statistic except that the standard errors have been moderated across genes, i.e., shrunk towards a common value, using a simple Bayesian model. This has the effect of borrowing information from the ensemble of genes to aid with the same inference about each individual gene (17) . Moderated t-statistics lead to p-values in the same way that ordinary t-statistics do except that the degrees of freedom are increased, reflecting the greater reliability associated with the smoothed standard errors. The most popular form of adjustment is 'fdr' which is Benjamini and Hochberg's method to control the false discovery rate (19) . The meaning of fdr adjusted pvalues is as follows. If all genes with a p-value below a threshold, e.g. of 0.05, are selected as differentially expressed, then the expected proportion of false discoveries in the selected group is controlled to be less than the threshold value, in this case 5%. The B-statistic is the log-odds that the gene is differentially expressed (15) . For example, if B=1.5, the odds of differential expression (1.5) =4.48; i.e., ~4.5:1. The probability that the gene is differentially expressed is 4.48/ (1+4.48)=0.82. A B-statistic of zero corresponds to a 50-50 chance that the gene is differentially expressed. The B-statistic is automatically adjusted for multiple testing by assuming that 1% of the genes, or some other percentage specified by the user referring to empirical Bayes (17) (18) (19) , is expected to be differentially expressed. The p-values and B-statistics will normally rank genes in the same order. In fact, if the data contains no missing values or quality weights, then the order will be precisely the same. As with all model-based methods, the p-values depend on normality and other mathematical assumptions which are never completely precise for microarray data. It has been argued that the p-values are useful for ranking genes even in the presence of large deviations from the assumptions. The B-statistic probabilities depend on the same assumptions but require in addition a prior estimate for the proportion of differentially expressed genes. The p-values may be preferred to the B-statistics because they do not require this prior knowledge (20) .
Results
Identification of differentially expressed genes in breast epithelium. Genes whose expression changes were considered to be statistically significant using established algorithms, and whose expression changed by at least 1.2-fold as a result of being a case, were selected for further analysis (19) . This combined analytic approach has previously been shown to be capable of identifying differentially expressed genes with high sensitivity and specificity (19) . We were able to identify gene sequences differentially expressed (t-test with false discovery rate p<0.05) in epithelium from the parous breast control compared to that from the parous breast cancer cases. We Table I . Upregulated genes in the parous control breast epithelia. Table I . Continued. found that 126 genes were upregulated (Table I ) and 103 were downregulated (Table II) (Table II) . This indicates that the programmed cell death is a signature prevalently expressed in the parous control group. The DNA repair process was also overrepresented in the parous control breast epithelia containing seven genes that were significantly upregulated (Table I) The third biological process overrepresented in the parous control group was the cluster of genes related to cell response either in the immunosurveillance category or response to genotoxic agents (Table I) Another biological process that was significantly overrepresented in the parous control breast epithelia is that controlling gene transcription/gene transcription-regulation in which 21 genes were upregulated and 12 were downregulated (Tables I and II) . Among these genes the Suppressor of Ty 5 homolog (SUPT5H), Homeo box D1 (HOXD1), p300/CBP associated factor (PCAF) and Inhibitor of DNA binding 4 (ID4) were highly upregulated in the control parous breast epithelia (Table I) .
Genomic signature of the breast interlobular stroma. There were only 56 differentially expressed genes in the interlobular stroma from parous control women (Table III) . The selection criteria was based on a B-value >0 and a p<0.05. We found 30 genes that were differentially overexpressed and 26 Table II . Downregulated genes in the parous control breast epithelia. genes that were downregulated in the parous control group (Table III) . There was no biological process overrepresented and most of the Gene Ontology revealed unknown biological function.
-------------------------------------------------

Discussion
In the present study we demonstrate that early first full-term pregnancy imprints a specific genomic signature in the breast epithelia of postmenopausal women that is significantly different from that of women that also have had an early full-term pregnancy but have developed cancer. The genomic signature is made up of 126 upregulated and 103 downregulated genes. The gene ontology categories that were overrepresented in the breast epithelia of the parous control breast are related to apoptosis, DNA repair, response to exogenous agents, and gene transcription/gene transcriptionregulation. There are 10 genes that control apoptosis that were differentially expressed in the breast epithelia of the parous women. Among them six were upregulated such as the BCL2-associated X protein (BAX) that belongs to the BCL2 protein family. BAX is a pro-apoptotic gene whose transcription is stimulated by active p53, including the pro-apoptotic gene p21, a cell cycle regulator (21) (22) (23) . This protein forms a heterodimer with BCL2, and functions as an apoptotic activator (24) . The expression of this gene is regulated by the tumor suppressor P53 and has been shown to be involved in P53-mediated apoptosis (21, 25) . Programmed cell death 5 (PDCD5) and Transformed 3T3 cell double minute 4 (Mdm4) were downregulated in the parous breast epithelia. The Mdm4 gene is amplified and overexpressed in a variety of human cancers and encodes structurally related oncoproteins that bind to the Table II. Continued. - Table II . Continued.
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- Table III . Gene expression profile of the stroma of the human breast.
- p53 tumor suppressor protein and inhibit p53 activity (26) (27) (28) (29) . Mice with deleted Mdm4 die during embryogenesis, and the developmental lethality in this model can be rescued by concomitant deletion of p53 (30) . The downregulation of the MDM4 in the breast of parous epithelia may act as a protective mechanism and be part of the program cell death pathway active in these cells. Altogether this cluster of genes seems to maintain the active programmed cell death pathway in the parous breast epithelia when compared with the parous breast of women with cancer. Supporting evidence for this statement comes from data in the experimental model (31) (32) (33) (34) and in the normal breast tissue from reduction mammoplasty specimens of parous women (7) (8) (9) , in which genes involved in the pathway of apoptosis were significantly upregulated.
----------------------------------------------------------------------------------------------------
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We have identified in the present study that upregulation of DNA repair controlling genes is part of the signature induced by pregnancy. This is supported by data generated in the experimental system in which the parous mammary epithelial cells have a higher ability to remove the DNA adducts of 7-12 dimethylbenz (a) anthracene (35, 36) . The greater ability of the parous mammary epithelial cells to remove the DNA adducts has been the first indication that an improved DNA repair was involved in the protective effect induced by pregnancy. DNA repair is central to the integrity of the human genome and reduced DNA repair capacity has been linked to genetic susceptibility to cancer (37) (38) (39) (40) . A reduced DNA repair is associated with risk of breast cancer in women (41) . The epithelial cells of the breast from parous control women present DNA repair related genes that are upregulated significantly when compared with the same gene expression in the epithelial cells of the parous women with cancer. RAD51-like 3 was upregulated in the epithelial cells of the parous breast and it is known to be involved in the homologous recombination and repair of DNA (42) (43) (44) .
Other genes related to the DNA repair process are Ankyrin repeat domain 17 (ANKRD17) and Translin (TSN), which encodes a DNA-binding protein that specifically recognizes conserved target sequences at the breakpoint junction of chromosomal translocations (45) . These data indicate that the activation of genes involved in the DNA repair process is part of the signature induced in the mammary gland by pregnancy, confirming previous findings that in vivo the ability of the cells to repair carcinogen-induced damage by unscheduled DNA synthesis and adduct removal is more efficient in the post-pregnancy mammary gland (35, 36) .
Another cluster of genes that are upregulated in the parous control group are those related to immunosurveillance and detoxification of xenobiotic substances. The concept that an immunological process was involved during pregnancy which is responsible for its protective effect in mammary carcinogenesis has been reported (46, 47) . In breast epithelial cells of parous postmenopausal women we found that the Toll-like receptor gene is upregulated. This gene belongs to the innate immune system recognizing microbial pathogens through Toll-like receptors (TLRs), which identify pathogenassociated molecular patterns (48, 49) . We have also found that the regulatory factor X-associated protein that is part of the major histocompatibility (MHC) class II molecules (50) is upregulated (8) . It is a transmembrane protein that has a central role in the development and control of the immune system. These data allow us to postulate that the increased immune-surveillance mechanism has been imprinted during the differentiation cycle induced by pregnancy and could be one of the protective factors induced by the cells against neoplastic initiation or progression.
In addition to this increase in the immune-surveillance mechanism in the breast of parous epithelia there are genes significantly upregulated and involved in the metabolism of xenobiotic substances and oxidative stress. Among them are the Epoxide hydrolase (EPHX1) that plays an important role in both the activation and detoxification of exogenous chemicals such as polycyclic aromatic hydrocarbons and the Thioredoxin reductase 1 (TXNRD1) that encodes a member of a family of pyridine nucleotide oxidoreductases. TXNRD1 protein reduces thioredoxins as well as other substrates, and plays a role in selenium metabolism and protection against oxidative stress (51, 52) . Thioredoxin reductase 1 is one of the major antioxidant and redox regulators in mammals that supports p53 function and other tumor suppressor activities (53, 54) . Glutathione Stransferase θ 1 (GSTT1) is a member of a superfamily of proteins that catalyzes the conjugation of reduced glutathione to a variety of electrophilic and hydrophobic compounds and is upregulated in the parous breast epithelia. The other gene that is also overexpressed is the N-acetyltransferase 2 [arylamine N-acetyltransferase (NAT2)] involved in the metabolism of different xenobiotics, including potential carcinogens. The upregulation of these genes is interpreted as an activated system of defense that makes the parous breast cells less vulnerable to genotoxic substances. This contention is supported by data indicating that primary breast epithelial cells from parous women treated in vitro with chemical carcinogens do not express phenotypes of cell transformation whereas those from nulliparous women do (55, 56) .
There are 21 genes encoding proteins controlling gene transcription/gene transcription-regulation that are significantly upregulated in the parous breast epithelia and 12 that are downregulated. This indicates that during pregnancy transcription modifications are important components of the genomic signature induced by this physiological process. Another group of genes associated with their function as coactivator and in chromatin remodeling seems to play an important role in the signature induced by pregnancy in the breast epithelial cells. One of them is the p300/CBP-associated factor (PCAF) that is significantly upregulated in the epithelial cells of the parous breast tissue (7) (8) (9) . PCAF is a coactivator of the tumor suppressor, p53. PCAF participates in p53's transactivation of target genes through acetylation of both bound p53 and histones within p53 target promoters (57) . The role of p300/CBP-associated factor in the differentiated breast epithelial cells of parous women could be similar to the effect of trans-retinoic acid (ATRA) treatment on metastatic breast cancer cells that, by increasing the protein levels of the histone acetyl transferases p300 and CBP, suppresses the level of histone deacetylase and increases the level of acetylated histone H4. ATRA also has been shown to decrease Bcl-2 and VEGF and increase BAX (58) . BAX is upregulated in the parous breast epithelial cells. PCAF has been considered part of the genomic signature of the Stem cell 2 (7-9).
ID4 (Inhibitor of DNA binding 4) is a member of the Id family of proteins (Id1-Id4), which function as dominantnegative regulators of basic helix-loop-helix transcription factors and are involved in numerous cell processes, including cell proliferation, and differentiation (59) . Id4 is constitutively expressed in the normal human mammary epithelium but is suppressed in breast carcinomas and preneoplastic lesions supporting a possible role of Id4 as a tumor suppressor factor in the human breast (59, 60) . Primary breast cancers have low or no expression of ID4 protein (61) and ID4 has also been considered a putative tumor-suppressor gene that is methylated in most mouse and human leukemias (62) (63) (64) (65) .
Altogether our data indicate that early first full-term pregnancy induces in the breast epithelia a specific genomic profile that can be identified in the postmenopausal breast and that makes these epithelial cells different to parous breast tissue from women with breast cancer. This genomic signature allows us to evaluate the degree of mammary gland differentiation induced by pregnancy and it could be the signature postulated for the Stem cell 2 (7) (8) (9) 66) . This signature could help to predict in which woman parity is protective, and it can be used as a biomarker for evaluating preventive agents.
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